CSL

CSL, headquartered in Melbourne, Australia, is a global biotechnology leader with operations in over 30 countries. Founded in 1916 and privatized in 1994, CSL develops and manufactures biotherapeutics, vaccines, and specialty pharmaceuticals aimed at treating rare and serious medical conditions. The company employs more than 32,000 people and reported $14.8 billion in revenue in 2024. CSL operates through four main divisions: CSL Behring, which specializes in plasma-derived therapies; CSL Plasma, which manages plasma collection networks; CSL Seqirus, a major producer of influenza vaccines; and CSL Vifor, focusing on therapies for iron deficiency and kidney disease. The company offers a range of products, including immunoglobulins, seasonal and pandemic vaccines, and iron deficiency treatments. CSL is committed to quality and innovation, maintaining a strong focus on patient needs and compliance with global regulatory standards.